RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough lymphoma
Disease control OngoingThis study tests adding a drug called selinexor to the standard chemotherapy RCHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than RCHOP alone. About 43 adults with advanced or returning lymphoma are ta…
Matched conditions: RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug cocktail shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis early-phase study tests the safety and best dose of a three-drug combination (venetoclax, lenalidomide, and rituximab) in adults with follicular or marginal zone lymphoma that has returned or not responded to prior treatment. The drugs work by blocking cancer cell survival s…
Matched conditions: RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated May 11, 2026 20:38 UTC